Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female infant or young child aged 28 days to \< 2 years with gestational age ≥ 33 weeks at screening.~2. Subject weighed between ≥ 3.0 kg and \< 15.0 kg at screening.~3. Subject is otherwise healthy but was hospitalized for and clinically diagnosed with RSV LRTI (bronchiolitis or broncho-pneumonia), i.e., showing typical clinical signs and symptoms such as tachypnea, wheezing, cough, crackles, use of accessory muscles and/or nasal flaring.~4. Subject had a positive RSV diagnostic test at screening.~5. Subject was expected to have to stay in the hospital for at least 24 hours (according to the Investigator's judgment at screening).~6. Symptoms were likely related to RSV infection (i.e., the symptoms present needed to be probably linked to the current RSV infection according to Investigator's judgment) had appeared within 4 days of screening and were not yet improving at screening and randomization.~7. Subject fulfilled at least 2 of the following RSV disease severity criteria at screening and randomization:~   * Inadequate oral feeding that required feeding support (i.e., nasogastric tube or intravenous \[i.v.\] line)~  * Inadequate oxygen saturation defined as:~     * Oxygen saturation (peripheral capillary oxygen saturation \[SpO2\]) ≤ 92% on room air or~    * Requiring oxygen supplementation to maintain oxygen saturation \> 90% with documented pre-supplementation value ≤ 92%~  * Signs of respiratory distress defined as:~     * Respiratory rate ≥ 50 per minute in infants up to 12 months of age, and ≥ 40 per minute in children above 12 months and/or~    * Moderate or marked respiratory muscle retractions~8. Normal psychomotor development.~Exclusion Criteria:~1. Subject was known to have significant comorbidities including:~   * Genetic disorders (e.g., trisomy 21, cystic fibrosis),~  * Hemodynamically significant congenital heart disease (e.g., needing corrective therapy or inotropic support),~  * Bronchopulmonary dysplasia,~  * Any hereditary or acquired metabolic (bone) diseases,~  * Hematologic or other malignancy.~2. Subject was known to be human immunodeficiency virus (HIV)-positive. If the subject was \< 6 months of age, a known HIV-positivity of the mother was also exclusionary.~3. Subject was known to be immunocompromised.~4. Subject had or was suspected to have an active, clinically relevant concurrent infection (e.g., bacterial pneumonia, urinary tract infection). Concurrent acute otitis media was not exclusionary.~5. Subject had significant oral and/or maxillofacial malformations that would prevent proper positioning of the face mask.~6. Subject received invasive mechanical ventilation or non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure) in the 4 weeks prior to screening.~7. During the admission, the subject was initially hospitalized in an intensive care unit (ICU) setting and/or had received invasive mechanical ventilation or non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure).~8. Subject was critically ill and/or was expected to require invasive mechanical ventilation, non invasive respiratory support (i.e., continuous or bilevel positive airway pressure), or High Flow oxygen therapy (HFOT) at levels not enabling nebulization therapy according to the Investigator's judgment. High Flow oxygen, with a maximum flow of 2 L/kg/min, was permitted under the following conditions:~   * used as Standard of Care outside ICU setting~  * could be removed for study drug administration (Note: oxygen flow at 2 L/min could be provided)

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- ALX-0171 3.0 mg/kg (Type: EXPERIMENTAL): Inhalation of ALX-0171 3.0 mg/kg once daily for 3 consecutive days
- ALX-0171 6.0 mg/kg (Type: EXPERIMENTAL): Inhalation of ALX-0171 6.0 mg/kg once daily for 3 consecutive days
- ALX-0171 Dose 9.0mg/kg (Type: EXPERIMENTAL): Inhalation of ALX-0171 9.0 mg/kg once daily for 3 consecutive days
- Placebo (Type: PLACEBO_COMPARATOR): Inhalation of Placebo once daily for 3 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).